미국의 자궁근종 치료 기기 시장 : 시장 규모, 점유율, 동향 분석 보고서 - 기술별, 치료 모드별, 부문 예측(2025-2030년)

U.S. Uterine Fibroids Treatment Devices Market Growth & Trends:

The U.S. uterine fibroids treatment devices market size is anticipated to reach USD 4.71 billion by 2030 and is anticipated to expand at a CAGR of 9.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. The U.S. uterine fibroids treatment devices industry is experiencing significant growth due to the rising awareness of fibroid treatment options, advancements in minimally invasive procedures, and increasing demand for uterus-preserving alternatives to hysterectomy. In addition, the growing prevalence of uterine fibroids among women of reproductive age and the availability of innovative treatment devices are key factors driving market expansion.

Innovations in fibroid treatment devices continue to transform patient care. Recent FDA approvals and product launches have concreted the way for more effective and less invasive treatment options. In September 2024, Gynesonics Inc., a medical device company specializing in minimally invasive solutions for symptomatic uterine fibroids, announced the release of its new SMART OS 2.4 software technology for the Sonata System. This innovative treatment combines the first and only intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, offering an incision-free, uterus-preserving, transcervical option for treating symptomatic uterine fibroids. Such advancements highlight the industry's commitment to improving patient outcomes while reducing procedural risks.

The market is shifting toward non-surgical and uterus-sparing treatment approaches. Traditional surgical procedures, such as hysterectomy, are being replaced by less invasive methods that offer reduced recovery time, fewer complications, and improved quality of life for patients. Hysteroscopic myomectomy, laparoscopic myomectomy, and non-invasive ultrasound therapy are gaining traction among patients and healthcare providers.

With ongoing technological advancements, increased insurance coverage for minimally invasive procedures, and a growing focus on women's reproductive health, the U.S. uterine fibroids treatment devices industry is poised for sustained growth.

U.S. Uterine Fibroids Treatment Devices Market Report Segmentation

• Based on technology, the surgical technologies segment dominates the market with the largest revenue share owing to the increasing prevalence of uterine fibroids among women, necessitating effective surgical interventions.
• Based on mode of treatment, the invasive treatment segment dominates the market with the largest revenue share owing to the high adoption of hysterectomy and myomectomy procedures, which offer definitive fibroid removal. Advancements in laparoscopic and robotic-assisted surgeries, along with strong insurance coverage, further solidified its market dominance.
• In January 2025, Hologic, Inc. acquired Gynesonics, Inc., a privately held company specializing in minimally invasive solutions for uterine fibroid treatment, for approximately USD 350 million. Gynesonics is renowned for its Sonata System, an innovative technology that combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation to treat symptomatic uterine fibroids without incisions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Third Party Perspective
  • 1.3.5. Primary research
  • 1.3.6. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Uterine Fibroids Treatment Devices Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of uterine fibroids
    • 3.2.1.2. Advancements in minimally invasive procedures
    • 3.2.1.3. Increasing awareness and early diagnosis
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of advanced treatment devices
• 3.3. U.S. Uterine Fibroids Treatment Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. U.S. Uterine Fibroids Treatment Devices Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Uterine Fibroids Treatment Devices Market Technology Movement Analysis
• 4.3. U.S. Uterine Fibroids Treatment Devices Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 4.4. Surgical Techniques
  • 4.4.1. Surgical Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Hysterectomy
    • 4.4.2.1. Hysterectomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Myomectomy
    • 4.4.3.1. Myomectomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Laparoscopic Techniques
  • 4.5.1. Laparoscopic Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Laparoscopic Myomectomy
    • 4.5.2.1. Laparoscopic Myomectomy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Myolysis
    • 4.5.3.1. Myolysis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Ablation Techniques
  • 4.6.1. Ablation Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.2. Microwave Abalation
    • 4.6.2.1. Microwave Abalation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.3. Hydrothermal Abalation
    • 4.6.3.1. Hydrothermal Abalation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.4. Cyroablation
    • 4.6.4.1. Cyroablation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.5. Ultrasound Abalation
    • 4.6.5.1. Ultrasound Abalation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.5.2. High Intensity Focused Ultrasound (HIFU)
      • 4.6.5.2.1. High Intensity Focused Ultrasound (HIFU) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.5.3. MRI-guided Focused Ultrasound (MRgFUS)
      • 4.6.5.3.1. MRI-guided Focused Ultrasound (MRgFUS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Embolization Techniques
  • 4.7.1. Embolization Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Uterine Fibroids Treatment Devices Market: Mode of Treatment Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Uterine Fibroids Treatment Devices Market Mode of Treatment Movement Analysis
• 5.3. U.S. Uterine Fibroids Treatment Devices Market Size & Trend Analysis, by Mode of Treatment, 2018 to 2030 (USD Million)
• 5.4. Invasive Treatment
  • 5.4.1. Invasive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Minimally Invasive Treatment
  • 5.5.1. Minimally Invasive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Non-invasive Treatment
  • 5.6.1. Non-invasive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Market Participant Categorization
• 6.2. Key Company Profiles
  • 6.2.1. Medtronic
    • 6.2.1.1. Company Overview
    • 6.2.1.2. Financial Performance
    • 6.2.1.3. Service Benchmarking
    • 6.2.1.4. Strategic Initiatives
• 6.3. Stryker
  • 6.3.1.1. Company Overview
  • 6.3.1.2. Financial Performance
  • 6.3.1.3. Service Benchmarking
  • 6.3.1.4. Strategic Initiatives
• 6.4. Boston Scientific Corporation
  • 6.4.1.1. Company Overview
  • 6.4.1.2. Financial Performance
  • 6.4.1.3. Service Benchmarking
  • 6.4.1.4. Strategic Initiatives
• 6.5. Insightec.
  • 6.5.1.1. Company Overview
  • 6.5.1.2. Financial Performance
  • 6.5.1.3. Service Benchmarking
  • 6.5.1.4. Strategic Initiatives
• 6.6. CooperSurgical Inc.
  • 6.6.1.1. Company Overview
  • 6.6.1.2. Financial Performance
  • 6.6.1.3. Service Benchmarking
  • 6.6.1.4. Strategic Initiatives
• 6.7. Hologic, Inc.
  • 6.7.1.1. Company Overview
  • 6.7.1.2. Financial Performance
  • 6.7.1.3. Service Benchmarking
  • 6.7.1.4. Strategic Initiatives
• 6.8. CONMED Corporation.
  • 6.8.1.1. Company Overview
  • 6.8.1.2. Financial Performance
  • 6.8.1.3. Service Benchmarking
  • 6.8.1.4. Strategic Initiatives
• 6.9. Merit Medical Systems.
  • 6.9.1.1. Company Overview
  • 6.9.1.2. Financial Performance
  • 6.9.1.3. Service Benchmarking
  • 6.9.1.4. Strategic Initiatives
• 6.10. Minerva Surgical, Inc.
  • 6.10.1.1. Company Overview
  • 6.10.1.2. Financial Performance
  • 6.10.1.3. Service Benchmarking
  • 6.10.1.4. Strategic Initiatives